Gfap - glial fibrillary acidic protein Gene

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 24387

Summary

Enables Integrin binding activity and kinase binding activity. A structural constituent of Cytoskeleton. Involved in positive regulation of glial cell proliferation; regulation of chaperone-mediated autophagy; and response to wounding. Located in astrocyte projection and cytoplasmic side of lysosomal membrane. Biomarker of brain edema and retinal disease. Human ortholog(s) of this gene implicated in Alexander disease. Orthologous to human GFAP (glial fibrillary acidic protein). [provided by Alliance of Genome Resources, Apr 2022]

Gfap Products (1)

mRNA Protein Name
NM_017009.2 NP_058705.2 glial fibrillary acidic protein

Gene Ontology

  • Molecular Function
  • Biological Process
  • Cellular Component
Molecular Function GO Annotation Evidence References Source
enables integrin binding IDA
IDA: Inferred from direct assay
16988027 RGD
enables kinase binding IPI
IPI: Inferred from physical interaction
11082283 RGD
enables protein binding IPI
IPI: Inferred from physical interaction
20797626 RGD
enables structural constituent of cytoskeleton IDA
IDA: Inferred from direct assay
11796520 RGD
Biological Process GO Annotation Evidence References Source
involved in positive regulation of glial cell proliferation IMP
IMP: Inferred from mutant phenotype
21250919 RGD
involved in regulation of chaperone-mediated autophagy IMP
IMP: Inferred from mutant phenotype
20797626 RGD
Cellular Component GO Annotation Evidence References Source
located in astrocyte projection IDA
IDA: Inferred from direct assay
12368262 RGD
located in cytoplasmic side of lysosomal membrane IDA
IDA: Inferred from direct assay
20797626 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

glial fibrillary acidic protein

  • glial fibrillary acidic protein alpha

  • glial fibrillary acidic protein delta

  • intermediate filament

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (2)
Cat. No. Product Name Effect
Purity Phase
HY-P3392A Zilganersen sodium Inhibitor 91.43% Phase 3
HY-P3392 Zilganersen 91.43% Phase 3

Pre-clinical Phase

Bioactive Molecules (11)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-148013 K284-6111 Inhibitor 99.94% Unkown
HY-W035091 Tetrachloroauric acid 97.0% Unkown
HY-W019710 (E,E)-RGFP966 Inhibitor 99.44% Unkown
HY-N6908 Continentalic acid 99.72% Unkown
HY-176311S GFAP, U-15N / Unkown
HY-181178 (Mor-Cor)Ag(III) Inhibitor / Unkown
HY-183796 GFAP/NF-κB/APOE/NLRP3-IN-1 Inhibitor / Unkown
HY-184108 ZL006-05 / Unkown
HY-RS05376 GFAP Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS17035 Gfap Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS23479 Gfap Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Gfap NCBI NCBI:2670